Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)

NCT ID: NCT01331811

Last Updated: 2015-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

441 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.

The aim of this study is to improve TB diagnosis in HIV-infected children by developing a new diagnostic algorithm incorporating new tools available such as:

* interferon gamma release assays (IGRAs), as alternative to the tuberculin skin test
* alternative specimen collection methods such as string test (or Enterotest (R)), nasopharyngeal aspirates and stools samples, as alternatives to gastric aspirate
* the Xpert MTB/RIF assay

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Tuberculosis Pediatrics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Development of a diagnosis algorithm

At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:

* interview on anamnesis
* clinical examination
* evaluation of HIV infection stage
* hematology and biochemistry tests
* CD4 count
* HIV viral load
* IGRA
* chest radiograph
* Abdominal ultrasonograph to detect abdominal lymphadenopathy
* Tuberculin skin test
* gastric aspirates, sputum and string tests according to the age of children
* nasopharyngeal aspirate
* stool sample
* lymph node fine needle aspirate or other specimen collection if applicable

Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children aged from 0 to 13 years
* confirmed HIV infection
* suspicion of tuberculosis
* informed consent signed by at least one parent or guardian
* on ARVs or not

Exclusion Criteria

* history of anti TB treatment started in the past 2 years
* on going tuberculosis treatment
* Suspicion of exclusive extra-thoracic tuberculosis
Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Pasteur, Cambodia

OTHER

Sponsor Role collaborator

National Pediatric Hospital, Cambodia

UNKNOWN

Sponsor Role collaborator

Angkor Hospital for Children

OTHER

Sponsor Role collaborator

Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam

OTHER

Sponsor Role collaborator

Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam

UNKNOWN

Sponsor Role collaborator

Number 2 Children's Hospital, Ho Chi Minh City

OTHER

Sponsor Role collaborator

Hôpital Necker-Enfants Malades, Paris, France

UNKNOWN

Sponsor Role collaborator

Groupe Hospitalier Pitie-Salpetriere

OTHER

Sponsor Role collaborator

CHRU Arnaud de Villeveuve, Montpellier, France

UNKNOWN

Sponsor Role collaborator

IRD, Yaounde, Cameroon

UNKNOWN

Sponsor Role collaborator

Fondation Chantal Biya,Yaounde, Cameroon

UNKNOWN

Sponsor Role collaborator

CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso

UNKNOWN

Sponsor Role collaborator

Centre Muraz

OTHER

Sponsor Role collaborator

Centre Pasteur du Cameroun

OTHER

Sponsor Role collaborator

Centre Hospitalier D'essos

OTHER

Sponsor Role collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olivier Marcy, MD

Role: STUDY_CHAIR

Institut Pasteur in Cambodia, Phnom Penh, Cambodia

Vibol Ung, MD

Role: STUDY_CHAIR

National Pediatric Hospital, Phnom Penh, Cambodia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Sourô Sanou

Bobo-Dioulasso, , Burkina Faso

Site Status

National Pediatric Hospital

Phnom Penh, , Cambodia

Site Status

Angkor Hospital for Children

Siem Reap, , Cambodia

Site Status

Centre Hospitalier d'Essos

Yaoundé, , Cameroon

Site Status

Centre Mère Enfant Chantal Biya

Yaoundé, , Cameroon

Site Status

Pediatric Hospital Nhi Dong 1

Ho Chi Minh City, , Vietnam

Site Status

Pediatric Hospital Nhi Dong 2

Ho Chi Minh City, , Vietnam

Site Status

Pham Ngoc Thach Hospital

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Burkina Faso Cambodia Cameroon Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Marcy O, Borand L, Ung V, Msellati P, Tejiokem M, Huu KT, Do Chau V, Ngoc Tran D, Ateba-Ndongo F, Tetang-Ndiang S, Nacro B, Sanogo B, Neou L, Goyet S, Dim B, Pean P, Quillet C, Fournier I, Berteloot L, Carcelain G, Godreuil S, Blanche S, Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP. A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis. Pediatrics. 2019 Sep;144(3):e20182065. doi: 10.1542/peds.2018-2065.

Reference Type DERIVED
PMID: 31455612 (View on PubMed)

Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyangoh S, Ouedraogo AS, Ung V, Msellati P, Tejiokem M, Nacro B, Inghammar M, Dim B, Delacourt C, Godreuil S, Blanche S, Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group. Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis. Clin Infect Dis. 2019 May 2;68(10):1750-1753. doi: 10.1093/cid/ciy897.

Reference Type DERIVED
PMID: 30689814 (View on PubMed)

Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, Nacro B, Ateba-Ndongo F, Tetang-Ndiang S, Ung V, Dim B, Neou L, Berteloot L, Borand L, Delacourt C, Blanche S; ANRS 12229 PAANTHER 01 Study Group. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study. Lancet HIV. 2018 Feb;5(2):e87-e95. doi: 10.1016/S2352-3018(17)30206-0. Epub 2017 Nov 23.

Reference Type DERIVED
PMID: 29174612 (View on PubMed)

Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C. Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children. Clin Infect Dis. 2016 May 1;62(9):1161-1168. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.

Reference Type DERIVED
PMID: 26908804 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANRS12229 PAANTHER 01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infant TB Infection Prevention Study
NCT02613169 COMPLETED PHASE2
Host Blood RNA Signatures for Diagnosis of TB
NCT05542511 ACTIVE_NOT_RECRUITING